Testicular Cancer a Bigger Threat to Young Men
Title: Testicular Cancer a Bigger Threat to Young MenCategory: Health NewsCreated: 1/2/2019 12:00:00 AMLast Editorial Review: 1/3/2019 12:00:00 AM
Is robotic retroperitoneal lymph node dissection a feasible option in the treatment of testicular cancer? How does it compare to the open approach?Current Opinion in Urology
PMID: 30866033 [PubMed - in process]
ConclusionThis large retrospective cohort study suggests that patients who used PPIs are at higher risk of developing gynecomastia. Clinicians may want to convey this information to male patients who require long ‐term PPI therapy.This article is protected by copyright. All rights reserved.
Covalent RNA modifications, such as N-6-methyladenosine (m6A), have been associated with various biological processes, but their role in cancer remains largely unexplored. m6A dynamics depends on specific enzymes...
Authors: Alsdorf W, Seidel C, Bokemeyer C, Oing C Abstract INTRODUCTION: With the implementation of platinum-based chemotherapy, germ cell tumors (GCTs) became a model for a curable solid tumor, with survival rates of 95% in all patients with>80% survival in metastatic stages. Areas covered: Herein, the authors review the current standards of adjuvant chemotherapy for stage I GCTs as well as first-line and salvage treatments for metastatic disease. Novel approaches for refractory disease are also reviewed. Expert opinion: Active surveillance should be considered for all stage I patients and is the preferred appr...
Mar ía A. Lavanderos, Juan P. Cayún, Ángela Roco, Christopher Sandoval, Leslie Cerpa, Juan C. Rubilar, Roberto Cerro, Sebastián Molina-Mellico, Cesar Celedón, Berta Cerda, Elena García-Martín, José A. G. Agúndez, Cristián Acevedo, Karina Peña, Dante D. Cáceres, Nelson M. Varela, Luis A. Quiñ ones
Adjuvant tx has no clinically significant long - term effect on total sperm number, concentration
Title: Testicular Cancer Treatment Doesn't Always Doom FertilityCategory: Health NewsCreated: 2/26/2019 12:00:00 AMLast Editorial Review: 2/27/2019 12:00:00 AM
Publication date: Available online 26 February 2019Source: Best Practice &Research Clinical HaematologyAuthor(s): Guru Subramanian Guru Murthy, Sameem AbedinAbstractThe cure rate for several solid tumour malignancies including breast cancers, head and neck cancers, bone cancers, and sarcoma has improved remarkably with the advent of neoadjuvant and adjuvant therapies. Unfortunately, exposure to chemotherapy or radiation as a part of these treatments exposes patients to the risk of subsequent myeloid malignancies. Therapy related myeloid malignancies have certain characteristic findings. They typically arise within 10 y...